CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 3.3

ph-index = 6

Forward Citations = 347(Granted Patents)

Company Filing History:

5 out of 5,081

Centre National De La Recherche Scientifique

patents

3 out of 3

Polyplus Transfection

patents

2 out of 247

Rhone-poulenc Rorer S.a.

patents

4. 2 out of 170

Universitéde Strasbourg

patents

5. 2 out of 3

Polyplus-transfection Sa

where one patent can have more than one assignee

Years Active: 1992-2017

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9676798 - Cationic oligonucleotides, automated methods for preparing same and their uses (2017-06-13),

2. 9243248 - Oligonucleotides for RNA interference and biological applications thereof (2016-01-26),

3. 9090648 - Cationic oligonucleotides, automated methods for preparing same and their uses (2015-07-28),

4. 8802640 - Oligonucleotides for RNA interference and biological applications thereof (2014-08-12),

5. 8399422 - Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications (2013-03-19),

6. 6172048 - Composition containing nucleic acids, preparation and uses (2001-01-09),

7. 6013240 - Nucleic acid containing composition, preparation and uses of same (2000-01-11),

8. 5846947 - Composition containing nucleic acids, preparation and uses (1998-12-08),

9. 5616745 - Lipopolyamines, their preparation and their use (1997-04-01),

10. 5476962 - New lipopolyamines, their preparation and their use (1995-12-19),

11. 5171678 - Lipopolyamines, their preparation and their use (1992-12-15),

Title: The Innovative Mind of Jean-Paul Behr

Introduction

Jean-Paul Behr, an accomplished inventor based in Strasbourg, France, has made significant contributions to the field of molecular biology through his inventive work. With a portfolio of 11 patents, Behr is recognized for developing methods and compositions that have profound implications for RNA interference and other biological applications.

Latest Patents

One of Jean-Paul Behr's latest patents focuses on "Cationic oligonucleotides, automated methods for preparing same and their uses." This invention encompasses oligonucleotide-oligocation molecules that can be synthesized via automated phosphoramidite chemistry. The molecules involve specified oligonucleotide and oligocation components, allowing for various modifications and applications, including potential therapeutic uses.

Another noteworthy patent covers "Oligonucleotides for RNA interference and biological applications thereof." This invention includes double-stranded oligonucleotides that can be utilized for therapeutic applications by targeting specific nucleic acid sequences within living cells.

Career Highlights

Throughout his career, Jean-Paul Behr has held significant roles in esteemed research institutions. He has contributed his expertise to the Centre National de la Recherche Scientifique, where he engaged in groundbreaking research. He also worked with Polyplus Transfection, gaining valuable experience in developing transfection methodologies.

Collaborations

Jean-Paul Behr has collaborated with notable individuals in his field, including Jean-Serge Remy and Jean-Philippe Loeffler. These collaborations have undoubtedly enriched his research and led to advancements in the applications of his inventions.

Conclusion

Jean-Paul Behr stands out as a prominent figure in the world of innovation and invention, particularly in the area of molecular biology. His extensive patent portfolio reflects his dedication to advancing scientific knowledge and improving therapeutic applications. With a strong foundation in research and collaboration, Behr continues to influence the future of biotechnological advancements.

This text is generated by artificial intelligence and may not be accurate.